Longeveron Inc. (NASDAQ:LGVN) CEO Mohamed Wa’el Ahmed Hashad Acquires 10,638 Shares

Longeveron Inc. (NASDAQ:LGVN) CEO Mohamed Wa’el Ahmed Hashad bought 10,638 shares of the stock in a transaction on Thursday, April 11th. The shares were bought at an average price of $2.35 per share, with a total value of $24,999.30. Following the acquisition, the chief executive officer now owns 19,616 shares of the company’s stock, valued at $46,097.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Longeveron Price Performance

LGVN opened at $1.69 on Friday. Longeveron Inc. has a 12 month low of $1.62 and a 12 month high of $44.00. The stock has a fifty day moving average price of $4.32 and a 200-day moving average price of $12.41. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.50 and a quick ratio of 1.50.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($2.50) EPS for the quarter, missing the consensus estimate of ($2.10) by ($0.40). The firm had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.21 million. Longeveron had a negative net margin of 3,020.17% and a negative return on equity of 209.14%. As a group, equities research analysts expect that Longeveron Inc. will post -8.5 earnings per share for the current year.

Hedge Funds Weigh In On Longeveron

Several institutional investors and hedge funds have recently bought and sold shares of LGVN. Citadel Advisors LLC purchased a new stake in shares of Longeveron during the 4th quarter valued at $44,000. Northern Trust Corp increased its position in Longeveron by 368.4% during the 4th quarter. Northern Trust Corp now owns 49,753 shares of the company’s stock valued at $68,000 after buying an additional 39,130 shares in the last quarter. Armistice Capital LLC purchased a new stake in Longeveron in the fourth quarter valued at about $2,497,000. Boothbay Fund Management LLC acquired a new stake in Longeveron in the second quarter worth about $254,000. Finally, Geode Capital Management LLC grew its stake in shares of Longeveron by 78.6% during the second quarter. Geode Capital Management LLC now owns 66,392 shares of the company’s stock worth $224,000 after acquiring an additional 29,212 shares during the last quarter. 10.01% of the stock is owned by hedge funds and other institutional investors.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors.